The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | CAR-T, bispecifics and MRD: how is treatment for multiple myeloma evolving?
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, gives his thoughts on how the treatment of multiple myeloma could evolve – including the continued use of CAR-Ts, the use of bispecific antibodies for maintenance therapy, and the importance of measurable residual disease (MRD) for patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Advisory Board/Consultant: Adaptive, Abbvie, Amgen, BMS, Janssen, Karyopharm, Legend, Oncopep, Millennium, Novartis, Pfizer DCT
Scientific Founder: Oncopep, DCT
